The beginning of a new era in understanding hepatitis C virus prevention

Journal of Infectious Diseases

Volumn 202, Issue 7, 2010, Pages 981-983

  Rich, Josiah D ^a   Taylor, Lynn E ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C ANTIBODY; PEGINTERFERON; RIBAVIRIN;

ANTIVIRAL THERAPY; DRUG COST; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION PREVENTION; INTRAVENOUS DRUG ABUSE; LIVER CIRRHOSIS; NONHUMAN; NOTE; PRIORITY JOURNAL; SYRINGE; UNITED STATES; VIRUS CULTURE; VIRUS TRANSMISSION; DISEASE TRANSMISSION; PREVALENCE; SUBSTANCE ABUSE;

HEPATITIS C; HUMANS; PREVALENCE; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES;

EID: 77956906279     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/656213     Document Type: Note

References (25)

1. Wise M, Bialek S, Finelli L, Bell BP, Sorvillo F. Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology 2008; 47:1128-1135.
2. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A: D study. Arch Intern Med 2006; 166:1632 1641.
3. Public Health Service inter-agency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B and hepatitis C. MMWR Recomm Rep 1991; 40:1-17.
4. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45:579-587.
5. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010; 8:280-288.
6. Berenguer J, Alvarez-Pellicer J, Martin PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50:407-413.
7. Fishbein DA, Lo Y, Reinus JF, Gourevitch MN, Klein RS. Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection. J Acquir Immune Defic Syndr 2004; 37:1367-1375.
8. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 2003; 36:97-100. (Pubitemid 36099103)
9. Mehta SH, Genberg BL, Astemborski J, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008; 33:126-133.
10. Grebely J, Raffa JD, Lai C, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat 2009; 16:352-358.
11. Falck-Ytter Y, Kale H, Mullen K, Sarbah S, Sorescu L, McCullough A. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002; 136:288-292.
12. Hagan H, Latka M, Campbell J, et al. Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities. Clin Infect Dis 2006; 42:669-672. (Pubitemid 43271380)
13. Ghosn J, Thibault V, Delaugerre C, et al. Sexually transmitted hepatitis C virus superinfection in HIV/hepatitis C virus coinfected men who have sex with men. AIDS 2008; 22:658-661.
14. Alter M. Epidemiology of hepatitis C. Hepatology 1997; 26:62S-65S.
15. Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004; 351:760-768.
16. Acute hepatitis C virus infections attributed to unsafe injection practices at an endoscopy clinic - Nevada, 2007. MMWR Morb Mortal Wkly Rep 2008; 57:513-517.
17. Fischer GE, Schaefer MK, Labus BJ, et al. Hepatitis C virus infections from unsafe injection practices at an endoscopy clinic in Las Vegas, Nevada, 2007-2008. Clin Infect Dis 2010; 51:267-273.
18. Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355:887-891.
19. Paintsil E, He H, Peters C, Lindenbach BD, Heimer R. Survival of hepatitis C virus in syringes: implication for transmission amonginjection drug users. J Infect Dis 2010; 202(7):984-990 (in this issue).
20. Ciesek S, Friesland M, Steinmann J, et al. How stable is the hepatitis C virus (HCV)? Environmental stability of HCV and its susceptibility to chemical biocides. J Infect Dis 2010; 201:1859-1866.
21. Abdala N, Stephens PC, Griffith BP, Heimer R. Survival of HIV-1 in syringes. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:73-80.
22. Abdala N, Reyes R, Carney JM, Heimer R. Survival of HIV-1 in syringes: effects of temperature during storage. Subst Use Misuse 2000; 35:1369-1383. (Pubitemid 30484353)
23. Aaron S, McMahon JM, Milano D, et al. Intranasal transmission of hepatitis C virus: virological and clinical evidence. Clin Infect Dis 2008; 47:931-934.
24. Macias J, Palacios RB, Claro E, et al. High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack. Liver Int 2008; 28:781-786.
25. Edlin BR, Carden MR. Injection drug users: the overlooked core of the hepatitis C epidemic. Clin Infect Dis 2006; 42:673-676.